(Reuters) - Nissen and Furberg said in interviews they were concerned that patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment diclofenac.
"All versions of Arcoxia should be taken off the market now," said Furberg, who along with Nissen had been outspoken critics of Merck's older arthritis drug Vioxx before it was withdrawn in September 2004 after being linked to heart attacks and strokes in long-term users.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment